Wognum Albertus W, Eaves Allen C, Thomas Terry E
StemCell Technologies, Inc, Vancouver, BC, Canada.
Arch Med Res. 2003 Nov-Dec;34(6):461-75. doi: 10.1016/j.arcmed.2003.09.008.
Hematopoietic stem cells (HSCs) are defined by their ability to repopulate all of the hematopoietic lineages in vivo and sustain the production of these cells for the life span of the individual. In the absence of reliable direct markers for HSCs, their identification and enumeration depends on functional long-term, multilineage, in vivo repopulation assays. The extremely low frequency of HSCs in any tissue and the absence of a specific HSC phenotype have made their purification and characterization a highly challenging goal. HSCs and primitive hematopoietic cells can be distinguished from mature blood cells by their lack of lineage-specific markers and presence of certain other cell-surface antigens, such as CD133 (for human cells) and c-kit and Sca-1 (for murine cells). Functional analyses of purified subpopulations of primitive hematopoietic cells have led to the development of several procedures for isolating cell populations that are highly enriched in cells with in vivo stem cell activity. Simplified methods for obtaining these cells at high yield have been important to the practical exploitation of such advances. This article reviews recent progress in identifying human and mouse HSCs and current techniques for their purification.
造血干细胞(HSCs)的定义是其在体内重新填充所有造血谱系并在个体寿命期间维持这些细胞产生的能力。由于缺乏用于造血干细胞的可靠直接标志物,其鉴定和计数依赖于功能性长期、多谱系的体内再填充试验。任何组织中造血干细胞的频率极低,且缺乏特定的造血干细胞表型,这使得它们的纯化和表征成为一个极具挑战性的目标。造血干细胞和原始造血细胞可通过缺乏谱系特异性标志物以及存在某些其他细胞表面抗原(如人类细胞的CD133以及小鼠细胞的c-kit和Sca-1)与成熟血细胞区分开来。对纯化的原始造血细胞亚群进行功能分析,已促成了几种分离富含具有体内干细胞活性细胞的细胞群体的方法的发展。以高产率获得这些细胞的简化方法对于此类进展的实际应用至关重要。本文综述了在鉴定人类和小鼠造血干细胞方面的最新进展以及当前用于其纯化的技术。